Iceland· IS-EU/1/16/1155/001-002
Kyntheum
A brodalumab product containing brodalumabum inn, registered in Iceland by LEO Pharma A/S*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Brodalumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC12 (brodalumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Brodalumab · ATC L04AC12
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Brodalumabum INN
- Manufacturer
- LEO Pharma A/S*
- Country
- Iceland (IS)
- ATC code
- L04AC12
- ATC class
- Brodalumab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean5881341,5 ml x2 áf.sprISK 196779
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
59 interactions on record for brodalumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Brodalumab · interactions on record
59 records
- 27 severe
- 25 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Brodalumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKYNTHEUMLEO Pharma A/S, Ballerup
- BelgiumKyntheum 210 mgLeo Pharma
- SpainKYNTHEUM 210 MG SOLUCION INYECTABLE EN JERINGA PRECARGADALeo Pharma A/S
- NorwayKyntheumLEO PHARMA A/S (Danmark)
- PolandKyntheumLEO Pharma A/S
- SwedenKyntheum 210 mg Injektionsvätska, lösning i förfylld sprutaLEO Pharma A/S
- Japanブロダルマブ(遺伝子組換え)協和キリン
- United StatesSiliqBausch Health US LLC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Kyntheum
- Liechtenstein · Kyntheum
- Norway · Kyntheum
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2301ca3c-f9ff-410b-9a80-c4d99348a871 GET /v1/drugs/2301ca3c-f9ff-410b-9a80-c4d99348a871?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "L04AC12",
"marketed": true,
"strength": "210 mg",
"ma_number": "EU/1/16/1155/001-002",
"substance": "Brodalumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í gigtarlækningum, húðsjúkdómum og ónæmisfræði.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42933"
}See everything about brodalumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.